Bimatoprost, a medication for glaucoma from Allergan, Inc., has this interesting warning in its product insert:
LUMIGAN® (bimatoprost ophthalmic solution) 0.03% has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes, and growth of eyelashes. (emphasis ours)
It turns out that some companies (including Allergan itself) are trying to capitalize on the eyelash-inducing side effect of bimatoprost, and are working on developing preparations to make women and men more attractive, without the mascara.
The Wall Street Journal has an eye opening article, featuring Allergan, cosmetics companies, the FDA, a federal raid, and billions of dollars at stake…